Dragon’s blood

Unique Topical
for the Relief of
Skin Conditions
Southeast Virginia
Technology Partnership Forum
June 15, 2010
43% of al reported skin
Any scratch, rash, bug bite, cut, abrasion, skin break
 Contact with an infected person or any surface
Surgery / hospital; elderly, nursing homes, diabetics, gyms www.dalosbio.com
Molluscum Contagiosum
 Contact with an infected person or any surface
 Day care centers, gyms, other child-friendly locations  Extreme problem for pediatricians and dermatologists www.dalosbio.com
MersaDermTM – for MRSA and other
skin infections
 90% increase in 10 years; over 200 M reported cases  More US deaths from MRSA than from AIDS  Average cost - $60 K / patient and $5 M / hospital  Drug resistance –> Bactroban / oral antibiotics  MersaDerm meets the growing unmet need
PoxiDermTM – for
Molluscum Contagiosum
 200 M cases worldwide and rising rapidly  Normal treatment is to scrape, cut, burn, freeze,  Pox (smal pox) family – benign but persistent  Dermatologists and Pediatricians at a loss  No effective antiviral available until PoxiDerm
Dalos Business Description
 BIO Award as “most innovative and commercializable”  Direct to Market, evidence-based products  75% increase in sales from Year 1 to Year 2 www.dalosbio.com
 Bactroban – drug resistance; same with oral Neosporin – no MRSA activity  No active topical products (or oral) Abhorrent in-office procedures Internet “remedies” with no basis www.dalosbio.com
Dalos Marketing Strategies
 Great responses at American Academy of Dermatology and  Drive consumers to internet store – www.dalosbio.com
 Traditional Distribution Channels (Chain stores)  Social Networking (Facebook, WebMD, internet sites) www.dalosbio.com
Dalos Partnering Strategies
 Like-focused companies in US and world  Military (many military applications) www.dalosbio.com
Other Dalos Products
 Shampoo, body wash, hand soap Now being purchased with MersaDerm and PoxiDerm www.dalosbio.com
Management Team
 Dr. Gary Pekoe – President & CEO  28 years pharma / biotech product development Scientific Advisory Committee
 James Leyden, MD, U of Pennsylvania Judith Wil iams, MD, Eastern Virginia Medical School Dennis West, PhD, Northwestern University Arnold Oppenheim, MD, VA Beach Dermatology Knox Van Dyke, PhD, West Virginia U www.dalosbio.com
U.S. Projections
MersaDerm Skin infections $ 1.2 BPoxiDerm  Al other products in pipeline add to upside  Figures based on achieving investment goals www.dalosbio.com
 We solve the problem with MRSA, Mol uscum Gary Pekoe, PhD
888 321-MRSA (6772)

Source: http://www.flcmidatlantic.org/pdf/BiomedtechForum-06152010/DalosBioPharma.pdf


Hemolytic uremic syndrome; pathogenesis, treatment,and outcomeRichard Siegler and Robert OakesThe hemolytic uremic syndrome (HUS) is the most commonAs with any syndrome, the hemolytic uremic syndromecause of acute renal failure in infants and young children,(HUS) is a constellation of features, namely the triad ofand is a substantial cause of acute mortality and chronicmicroangiopathic hemol

Socket mobile power pack datasheet - version ii

F E A T U R E S Mobile Power for Your Mobile Life Portable Power Outlet! No power outlet available? Socket’s got the solution! Now you can re-charge your portable electronicdevices wherever and whenever. From coffee shops totrain stations, on the plane or on the road, theSocket Mobile Power Pack is the ultimate power source Simplify your Mobile Power Needs! The S

Copyright ©2018 Sedative Dosing Pdf